Dr. Ryan Ungaro
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Icahn School of Medicine at Mount Sinai (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 61
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Icahn School of Medicine at Mount Sinai
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
NY license 260703
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mount Sinai Hospital New York, NY
Medical groups
- Icahn School of Medicine at Mount Sinai (2,843 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 61
- Services billed
- 101
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 24 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Mesalamine Other prescribers in New York, NY | 34 |
| Stelara (ustekinumab) | 31 |
| Xeljanz (tofacitinib citrate) | 14 |
| Remicade (infliximab) | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 34 payments worth $45,014 in total to this clinician.
| AbbVie Inc. | $25,935 |
|---|---|
| Janssen Global Services, LLC | $8,699 |
| Pfizer Inc. | $6,436 |
| Genentech USA, Inc. | $3,711 |
| Janssen Biotech, Inc. | $211 |
| Lilly USA, LLC | $21.10 |
| Consulting Fee | $29,234 |
|---|---|
| Travel and Lodging | $9,202 |
| Compensation for services other than consulting (speaking, faculty) | $5,558 |
| Food and Beverage | $1,020 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Jun 24, 2025 | Consulting Fee | $13,475 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging travel to HOOFDDORP, Netherlands · in-kind | $7,383 |
| Janssen Global Services, LLC Feb 1, 2025 | Consulting Fee TREMFYA · Immunology | $7,098 |
| Pfizer Inc. Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) VELSIPITY · INFLAMMATION;PAIN | $5,558 |
| AbbVie Inc. Dec 18, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $3,675 |
| Genentech USA, Inc. Feb 5, 2025 | Consulting Fee | $3,525 |
| Janssen Global Services, LLC Dec 1, 2025 | Consulting Fee TREMFYA · Immunology | $1,461 |
| Pfizer Inc. Mar 21, 2025 | Travel and Lodging VELSIPITY · INFLAMMATION;PAIN · travel to New York, NY · in-kind | $835 |
| AbbVie Inc. Jun 2, 2025 | Travel and Lodging travel to HOOFDDORP, Netherlands · in-kind | $203 |
| AbbVie Inc. Jun 3, 2025 | Travel and Lodging travel to HOOFDDORP, Netherlands · in-kind | $203 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 18, 2025 | Consulting Fee SKYRIZI · IMMUNOLOGY | $3,675 |
| Janssen Global Services, LLC Dec 1, 2025 | Consulting Fee TREMFYA · Immunology | $1,461 |
| AbbVie Inc. Jun 24, 2025 | Consulting Fee | $13,475 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging travel to HOOFDDORP, Netherlands · in-kind | $7,383 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging travel to HOOFDDORP, Netherlands · in-kind | $179 |
| AbbVie Inc. Jun 4, 2025 | Travel and Lodging travel to HOOFDDORP, Netherlands · in-kind | $203 |
| AbbVie Inc. Jun 3, 2025 | Travel and Lodging travel to HOOFDDORP, Netherlands · in-kind | $203 |
| AbbVie Inc. Jun 2, 2025 | Travel and Lodging travel to HOOFDDORP, Netherlands · in-kind | $203 |
| AbbVie Inc. Jun 2, 2025 | Travel and Lodging travel to HOOFDDORP, Netherlands · in-kind | $197 |
| Pfizer Inc. Apr 1, 2025 | Compensation for services other than consulting (speaking, faculty) VELSIPITY · INFLAMMATION;PAIN | $5,558 |
| Pfizer Inc. Mar 21, 2025 | Travel and Lodging VELSIPITY · INFLAMMATION;PAIN · travel to New York, NY · in-kind | $835 |
| Genentech USA, Inc. Feb 5, 2025 | Consulting Fee | $3,525 |
| Janssen Global Services, LLC Feb 1, 2025 | Consulting Fee TREMFYA · Immunology | $7,098 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $66,421 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-blind, Placebo-Controlled Phase 3b Study to Evaluate the Short- and Long-term Efficacy and Safety of Dual Targeted Therapy With Intravenous Vedolizumab and Oral Upadacitinib Compared With Intrav…
Takeda Pharmaceuticals U.S.A., Inc. - A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)
Genentech, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.